AP&T: 纤维化分期仍是原发性胆源性胆管炎预后的独立预测因子

2019-11-28 不详 MedSci原创

尽管肝纤维化在原发性胆源性胆管炎(PBC)患者的危险分层中的确切作用尚不确定,但纤维化分期可预测慢性肝病患者的预后。因此,本项研究旨在评估基线纤维化分期在生化风险分层背景下预测长期预后的效能。

背景
尽管肝纤维化在原发性胆源性胆管炎(PBC)患者的危险分层中的确切作用尚不确定,但纤维化分期可预测慢性肝病患者的预后。因此,本项研究旨在评估基线纤维化分期在生化风险分层背景下预测长期预后的效能。

方法
在一个具有全球代表性的大型PBC患者队列中,研究人员对1980年至2014年的患者进行的肝活检进行了评估。除1年治疗反应外以及组织学无创性纤维化指标(AST / ALT比[AAR],AST与血小板比指数[APRI]),组织学纤维化分期的预测能力以及治疗1年的反应能力,FIB-4),采用Cox比例风险模型评估了无移植生存期。

结果
本项研究共有1828例肝活检患者。除非侵入性纤维化措施外,晚期组织学纤维化(3/4期)是生存率的独立预测指标,危险比范围为1.59至2.73(P  <.001)。尽管进行了生化治疗反应,但具有晚期组织学纤维化阶段的患者的生存期较差,根据所使用的治疗反应标准,其10年生存率为76.0%-86.6%。

结论
纤维化分期的评估可提供超过1年生化治疗反应的预后价值。这凸显了将纤维化阶段纳入PBC患者的个体风险分层的必要性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804458, encodeId=83f01804458d0, content=<a href='/topic/show?id=b52de7228ed' target=_blank style='color:#2F92EE;'>#纤维化分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77228, encryptionId=b52de7228ed, topicName=纤维化分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Thu Aug 13 23:40:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846833, encodeId=4013184683397, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 13 02:40:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310740, encodeId=243e1310e4068, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628406, encodeId=3092162840616, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375977, encodeId=337d3e597793, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Nov 29 07:32:41 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804458, encodeId=83f01804458d0, content=<a href='/topic/show?id=b52de7228ed' target=_blank style='color:#2F92EE;'>#纤维化分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77228, encryptionId=b52de7228ed, topicName=纤维化分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Thu Aug 13 23:40:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846833, encodeId=4013184683397, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 13 02:40:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310740, encodeId=243e1310e4068, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628406, encodeId=3092162840616, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375977, encodeId=337d3e597793, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Nov 29 07:32:41 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804458, encodeId=83f01804458d0, content=<a href='/topic/show?id=b52de7228ed' target=_blank style='color:#2F92EE;'>#纤维化分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77228, encryptionId=b52de7228ed, topicName=纤维化分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Thu Aug 13 23:40:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846833, encodeId=4013184683397, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 13 02:40:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310740, encodeId=243e1310e4068, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628406, encodeId=3092162840616, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375977, encodeId=337d3e597793, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Nov 29 07:32:41 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804458, encodeId=83f01804458d0, content=<a href='/topic/show?id=b52de7228ed' target=_blank style='color:#2F92EE;'>#纤维化分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77228, encryptionId=b52de7228ed, topicName=纤维化分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Thu Aug 13 23:40:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846833, encodeId=4013184683397, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 13 02:40:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310740, encodeId=243e1310e4068, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628406, encodeId=3092162840616, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375977, encodeId=337d3e597793, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Nov 29 07:32:41 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804458, encodeId=83f01804458d0, content=<a href='/topic/show?id=b52de7228ed' target=_blank style='color:#2F92EE;'>#纤维化分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77228, encryptionId=b52de7228ed, topicName=纤维化分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Thu Aug 13 23:40:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846833, encodeId=4013184683397, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 13 02:40:00 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310740, encodeId=243e1310e4068, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628406, encodeId=3092162840616, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Nov 30 14:40:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375977, encodeId=337d3e597793, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Nov 29 07:32:41 CST 2019, time=2019-11-29, status=1, ipAttribution=)]
    2019-11-29 txqjm

    谢谢了,学习

    0

相关资讯

Clin Trans Gastroenterology: 一种用于判断慢性乙型肝炎患者的肝纤维化的新型非侵入方案

慢性乙型肝炎(CHB)可进展为肝纤维化和肝硬化,预后不佳。早期准确诊断肝纤维化/肝硬化对于指导其相关并发症的预防策略非常重要。因此,本项研究旨在开发一种新型的模型来帮助CHB患者的治疗。

BMC Gastroenterology:标准和改良肠道准备在成人囊性纤维化患者中行结肠镜检查时的疗效比较

据报道,患有囊性纤维化(CF)的成人患结直肠癌(CRC)的风险是一般人群的5到10倍。在本项研究中,研究人员比较了两种肠道准备方案,标准肠道准备和改良的CF肠道准备在患者行结肠镜检查中的疗效差别。

Clin Gastroenterology H:内窥镜扩张胃十二指肠克罗恩病的功效

内镜球囊扩张术(EBD)对克罗恩病(CD)患者上消化道(UGI)狭窄的效果目前还不明确。本项研究旨在对EBD对UGI CD相关狭窄的疗效和安全性进行分析。

Clin Gastroenterology H: 克罗恩病患儿血浆Ⅲ型胶原α1链的水平与肠道狭窄发展的关系

目前,还没有公认的血清生物标志物可用于鉴定患有狭窄发展风险的克罗恩病(CD)患者。细胞外基质成分——III型胶原α1链(COL3A1)和软骨寡聚基质蛋白(COMP)可能导致肠纤维化。本项研究探究了患有炎症性CD(B1)后来发生狭窄(B2)的儿童,与持续B1的儿童相比,血清中是否增加了COL3A1或COMP的血浆水平。

Liver International: 长期使用核苷类似物对慢性乙型肝炎患者脂肪因子与肝脂肪变性和纤维化的影响

目前尚不清楚肝脂肪变性如何影响慢性乙型肝炎(CHB)的疾病进展。脂肪细胞因子如成纤维细胞生长因子21(FGF21)和脂肪细胞脂肪酸结合蛋白(AFABP)与非酒精性脂肪肝疾病有关。因此本项研究旨在探究这些代谢标志物在CHB相关肝损伤中的重要性。

Critical Care Medicine: 成纤维细胞可以作为脓毒性休克患者生存预测指标

体内内皮细胞和纤维蛋白的表达水平与脓毒性休克患者和非感染性休克患者的循环内皮细胞是否转化为活化的成纤维细胞有关,而这种循环内皮细胞蛋白表达变化是否是预测脓毒症存活的生物标志物目前还没有定论,本项研究旨在探究二脂之间的关系。